CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 131 enrolled
Drug / intervention
Vareniclinedrug
Likely dose
Varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01553136
NCT01553136Phase 2Completed
CompareCT.gov

1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers

Yale University·interventional·Posted Mar 13, 2012·Updated Mar 6, 2020

In Brief

A Phase 2 clinical trial evaluating Varenicline for Alcoholism and 3 related conditions. Completed, enrolled 131 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine whether varenicline is effective in the treatment of alcohol dependence in smokers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism, Alcohol Abuse, Smoking, Alcohol Drinking
CountriesUnited States
CollaboratorsColumbia University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2012
Enrollment StartSep 1, 2012
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.3 years ago

Interventions

Vareniclinedrug

0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day